Scleroderma (systemic sclerosis) is a generalized disorder characterized by intense scarring of the skin, lungs, gut, heart and kidneys; closely associated with this interstitial fibrosis is an intimal vascular and microvascular lesion throughout the body characterized by endothelial perturbation, intimal proliferation (smooth muscle cells), mononuclear cell infiltrates in the perivascular region, and vascular insufficiency of critical organ function which defines the prognosis and outcome in the individual patient. Increased understanding of scleroderma, which is the third most prevalent rheumatic disease (after rheumatoid arthritis and lupus) and which forms the bedrock for a number of diffuse connective tissue disorders (overlap syndromes, undifferentiated connective tissue syndromes (UCTS), mixed connective tissue disease (MCTD), Sjogren's associated syndromes, etc.), has come from study of the target cells (fibroblasts, smooth muscle cells, endothelial cells), from the matrix proteins synthesized and secreted, from serum activity studies, from serological studies of antinuclear and antimatrix antibodies, and from studies of immune cells and related cytokines (interleukins, interferons). We will study the growth regulation and gene expression of the scleroderma fibroblast and the interaction of endothelial cells with characterized recombinant cytokines, with serum activities, and with mononuclear cell and lymphocyte interactions relevant to the vascular and fibrotic manifestations of this untreatable and essentially incurable disease. We propose an in-depth cellular and molecular analysis of scleroderma; the hypothesis is that target cells are persistently activated and that the gene expression of this activation state can be studied directly by techniques of transfection, gene isolation, and gene sequencing to determine the molecular basis of abnormal competence or growth regulation genes in scleroderma. By studies combining several disciplines, we hope to integrate the presently disparate findings in this disease toward a logical and effective therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR030431-10
Application #
3155802
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1982-01-01
Project End
1992-06-30
Budget Start
1991-01-01
Budget End
1992-06-30
Support Year
10
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Yamakage, A; Kikuchi, K; Smith, E A et al. (1992) Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 175:1227-34
Kikuchi, K; Yamakage, A; Smith, E A et al. (1992) Differential modulation of bFGF receptors by TGF-beta in adult skin, scleroderma skin, and newborn foreskin fibroblasts. J Invest Dermatol 99:201-5
Xu, W D; Leroy, E C; Smith, E A (1991) Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta. J Rheumatol 18:241-6
Miller, K S; Smith, E A; Kinsella, M et al. (1990) Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity. Am Rev Respir Dis 141:301-6
Silver, R M; Miller, K S; Kinsella, M B et al. (1990) Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 88:470-6
Walker, M A; Harley, R A; DeLustro, F A et al. (1989) Adoptive transfer of tsk skin fibrosis to +/+ recipients by tsk bone marrow and spleen cells. Proc Soc Exp Biol Med 192:196-200
Kinsella, M B; Smith, E A; Miller, K S et al. (1989) Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum 32:577-83
Kahaleh, M B; Smith, E A; Soma, Y et al. (1988) Effect of lymphotoxin and tumor necrosis factor on endothelial and connective tissue cell growth and function. Clin Immunol Immunopathol 49:261-72
McGregor, A R; Watson, A; Yunis, E et al. (1988) Familial clustering of scleroderma spectrum disease. Am J Med 84:1023-32